ArticleActa pharmacologica Sinica2026
Fangchinoline restores TFEB-driven lysosomal biogenesis and blocks H1N1 infection.
Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fangchinoline (2021-2026): A Multitarget Bisbenzylisoquinoline Alkaloid With Emerging Anti-Infective Potential.Journal of tropical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza A viruses subvert lysosomal function to evade host degradation mechanisms. Using Connectivity Map (CMap) screening and transcriptomic analysis, we identified fangchinoline (Fan)-a bisbenzylisoquinoline alkaloid-as a potent enhancer of lysosomal gene expression. Owing to its alkaline properties, Fan accumulates within lysosomes, elevates luminal pH, and induces TFEB nuclear translocation, thereby restoring lysosomal biogenesis and initiating a TFEB-driven antiviral response. Concurrently, Fan disrupts autophagosome-lysosome fusion and impairs autophagic flux, further enhancing its antiviral activity. Time-resolved functional assays demonstrate that Fan primarily inhibits H1N1 infection at the entry stage by obstructing endolysosomal trafficking. Together, these results identify Fan as a novel TFEB-mediated lysosomal modulator that antagonizes influenza infection by counteracting viral lysosomal evasion strategies and highlighting the therapeutic potential of lysosome-targeted compounds in influenza treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.